WALGREENS BOOTS NOQ:.VAR


| Cash Assets |  |  |  |
| :---: | :---: | :---: | :---: |
| Cash Assets | $\begin{aligned} & 3301 \\ & 6528 \end{aligned}$ | 785 6573 | 7144 |
| Inventory (LIFO) | 8899 | 9565 | 10976 |
| Other | 1025 | 923 | 983 |
| Current Assets | 19753 | 17846 | 20083 |
| Accts Payable | 12594 | 13566 | 14660 |
| Debt Due | 251 | 1966 | 4344 |
| Other | 5802 | 6135 | 6095 |
| Current Liab. | 18547 | 21667 | 25099 |


| ANNUAL RATES | Past | Past |  |
| :--- | :---: | :---: | :---: |
| Est'd '15-' 17 |  |  |  |
| of change (per sh) | 10 Yrs. | 5 Yrs. | to '22.24 |
| Sales | $8.5 \%$ | $7.0 \%$ | $9.0 \%$ |
| "Cash Flow" | $10.0 \%$ | $11.0 \%$ | $10.0 \%$ |
| Earnings | $10.0 \%$ | $13.0 \%$ | $11.0 \%$ |
| Dividends | $18.0 \%$ | $13.0 \%$ | $7.0 \%$ |
| Book Value | $10.5 \%$ | $10.0 \%$ | $7.5 \%$ |


| Fiscal <br> Year <br> Ends | QUARTERLY SALES (\$ mill.) A |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Nov.30 | Feb.28 | May 31 | Full <br> Fiscal |  |  |
| 2016 | 29033 | 30184 | 29498 | 28636 | 117351 |
| Year |  |  |  |  |  |$|$

BUSINESS: Walgreens Boots Alliance, Inc. is the world's premiere drug distributor, anchored by its network of drugstores in North America and Europe. As of $8 / 31 / 17$, it operated 12,822 stores across the globe, including 8,100 locations in 50 states and Puerto Rico. In 2017, pharmacy contributed $69.0 \%$ of sales (3rd party, $97.7 \%$ of Rx ); Other general merchandise, 31.0\%. Stores average
Shares of Walgreens Boots Alliance have come under significant pressure on multiple occasions since our December review. Initially, they fell off a cliff shortly after the release of the said report, losing about 25\% in value. While the stock began to retrace some of those losses in the days that followed, it tumbled again in the last few weeks, and is currently testing multiyear lows.
Near-term earnings prospects appear
more challenging than in the past. AI
though the company announced solid, and better-than-expected, first-quarter results (fiscal years end August 31st), there are some concerns. Specifically, the Retail Pharmacy International business registered a 5.9\% top-line decline. This segment is likely to continue to be hurt by currency headwinds, the divestiture of Boots Contract Manufacturing, and soft business conditions in the U'nited Kingdom. The Retail Pharmacy USA (pharmacy and retail combined) segment enjoyed a 14.4\% top-line increase, but organic sales increased a far-less-impressive 4.6\% gain excluding the benefits of Rite Aid stores. Comparable-pharmacy sales were up $2.8 \%$,
$\$ 9.22$ million in annual sales. Has approximately 345,000 employees. Acquired 2,186 Rite Aid stores in September, 2017. Officers \& directors own 14.48\% of common stock. Vanguard, 6.5\%; BlackRock, Inc., 5.5\% (12/17 Proxy). CEO; Stefano Pessina. Chairman: James A. Skinner. Inc.: IL. Address: 108 Wilmot Road, Deerfield, IL 60015. Telephone: 847-914-2500. Internet: www.walgreens.com
but comparable-retail sales were down $3.2 \%$. We think that top-line growth will continue to slow due to the aforementioned factors, as well as management's decision to demphasize tobacco-related products, and that earnings growth will be further limited by reimbursement pressures among other things. Rival CVS' most recent quarterly report exasperated many of these concerns. Management left intact its fiscal 2019 7\%-12\% share-earnings growth forecast, but we have shaved our call by a nickel, to \$6.55. Our initial 2020 estimates look for more of the same. In that vein, we are looking for earnings of $\$ 7.05$ a share next year.
We continue to like these timely shares. While the industry landscape is likely to remain tough near term, Walgreens is a leader whose finances and size give it the wherewithal to persevere. L onger term, the recently announced costcutting initiative is expected to yield \$1 billion in annual cost savings by the conclusion of the third year. Total return prospects are even brighter on a riskadjusted basis.
AndreJ. Costanza
March 15, 2019 of it may be reproduced, resold, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product.

Company's Financial Strength Stock's Price Stability
Price Growth Persistence
Earnings Predictability

